CONCLUSION: GOLPH3, MYO18A, PITPNC1, and RAB1B maybe promising diagnostic and prognostic biomarkers in AML patients.
Biomarkers. 2023 Mar 15:1-15. doi: 10.1080/1354750X.2023.2191166. Online ahead of print.
ABSTRACT
INTRODUCTION: The role of different Golgi signaling proteins remains unexplored in the progression and spread of Acute myeloid leukemia (AML), whom all interact together in a way that facilitates proliferation and differentiation of myeloid lineage cells.Material & methods: This study comprised 70 newly diagnosed AML patients and 20 healthy controls to investigate the serum levels of signaling proteins; Golgi Phosphoprotein 3 (GOLPH3), Myosin 18A (MYO18A), Cytoplasmic Phosphatidylinositol Transfer Protein 1 (PITPNC1), and Ras-Associated Binding Protein 1B (RAB1B).
RESULTS: AML patients showed higher serum levels of GOLPH3, MYO18A, PITPNC1, and RAB1B when compared to control (p < 0.001). A significant negative correlation was found between the patients’ overall survival and GOLPH3 (p = 0.001), MYO18A (p = 0.011), PITPNC1 (p = 0.001), and RAB1B (p = 0.042). Results were confirmed by Kaplen-Meier survival analysis showing lower survival estimates in patients with higher GOLPH3 (p = 0.014), MYO18A (p = 0.047), PITPNC1 (p = 0.008) and RAB1B (p = 0.033) serum levels.
DISCUSSION: Golgi apparatus acts as master brain in membrane trafficking and signaling events that affect cell polarity necessary for migration, division, or differentiation. This study aims to explore the association between signaling proteins and the diagnosis, prognosis, and survival of AML patients.
CONCLUSION: GOLPH3, MYO18A, PITPNC1, and RAB1B maybe promising diagnostic and prognostic biomarkers in AML patients.
PMID:36919644 | DOI:10.1080/1354750X.2023.2191166
English
Arabic
Russian
French
Chinese (Simplified)
Japanese
Portuguese
Spanish